Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
ET
- ET
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), today announced its first quarter 2024 financial results and business highlights. - EMPAVELI for the treatment of PNH:
Generated $25.6 million in EMPAVELI U.S. net product revenue in the first quarter of 2024. - Apellis reported a net loss of $66.4 million for the first quarter 2024, compared to a net loss of $177.8 million for the same period in 2023.
- Apellis will host a conference call and webcast to discuss its first quarter 2024 financial results and business highlights today, May 7, 2024, at 8:30 a.m.